ADC Therapeutics is a commercial-stage biotechnology company focused on oncology. They are dedicated to developing Antibody Drug Conjugates (ADCs) for patients with hematological malignancies and solid tumors. Their goal is to transform the lives of individuals impacted by cancer.

Their flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), is designed to provide effective cancer treatment. ADC Therapeutics also has a robust pipeline of potential therapies, including loncastuximab tesirine-lpyl, camidanlumab tesirine, ADCT-602, Mipasetamab uzoptirine (ADCT-601), and ADCT-901. The company's approach is rooted in advanced technology and a deep understanding of the science behind ADCs.

They prioritize collaboration and accountability, striving to innovate with an entrepreneurial spirit. Additionally, ADC Therapeutics values the well-being of their employees and fosters a supportive working environment. Joining ADC Therapeutics means being part of an exciting professional opportunity, with competitive compensation and rewards.

They offer comprehensive benefits programs, including bonuses, retirement plans, and employee stock purchase plans. There are also opportunities for learning and development, a hybrid working environment, and a focus on employee health and well-being